Durata Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013

Durata Therapeutics to Announce First Quarter 2013 Financial Results on May 9,
2013

Conference Call to Be Held at 8:30 A.M. Eastern Time

CHICAGO, May 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has
scheduled its quarterly conference call for Thursday, May 9 at 8:30 a.m.
Eastern Time to discuss first quarter 2013 financial results.

The conference call will be available via phone and webcast. To access the
call, please dial 866-632-4021 for participants in the U.S. or Canada and
404-991-3968 for international callers (reference Conference ID 63029636). A
replay of the call may be accessed through May 23, 2013 by dialing
800-585-8367 for callers in the U.S. and Canada and 404-537-3406 for
international callers (reference Conference ID 63029636). The conference call
will also be webcast live on the Investor Relations section of the Company's
website at www.duratatherapeutics.com.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed its DISCOVER 1 and DISCOVER 2 global
Phase 3 clinical trials with its lead product candidate, dalbavancin, for the
treatment of patients with acute bacterial skin and skin structure infections,
or ABSSSI.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans
and prospects constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, as amended. Actual results
may differ materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will cause its
views to change. However, while Durata may elect to update these
forward-looking statements at some point in the future, Durata specifically
disclaims any obligation to do so.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey - Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312)219-7017 - awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.